RARE earnings call for the period ending March 31, 2019.
News & Analysis: Ultragenyx Pharmaceutical
RARE earnings call for the period ending December 31, 2018.
These stocks helped put downward pressure on the market. Find out why.
Ultragenyx's shares are reeling after the company's experimental drug for muscle-wasting disease fails in a late-stage study.
The drugmaker appears to have a potential blockbuster on its hands.
A slew of positive clinical data sends shares higher.
Clinton jumps into the drug-pricing fray, leading investors in rare-disease drug developers to panic.
Ultragenyx shares aren't looking so "ultra" today after the company announced its intention to sell shares of common stock. Find out what this means for investors.
MannKind receives favorable news from the FDA while Vertex stuns investors. Plus, three additional biotech companies deliver encouraging clinical results.
Ultragenyx delivers stellar early stage results in a phase 1/2 study. Could shares head even higher?